表紙
市場調査レポート

Sorrento Therapeutics, Inc. の製品パイプライン分析

Sorrento Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 320383
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Sorrento Therapeutics, Inc. の製品パイプライン分析 Sorrento Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 105 Pages
概要

Sorrento Therapeutics, Inc. は米国に本社を置くバイオ製薬企業です。癌および関連の疼痛を治療するための低分子治療薬、抗体薬物複合体(ADC)、抗体薬の開発を行っています。パイプライン製品には、ナノ粒子パクリタキセルであり、転移性乳癌・膵臓癌・非小細胞肺癌治療薬のCynviloqがあります。

当レポートでは、Sorrento Therapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Sorrento Therapeutics, Inc. の基本情報

  • Sorrento Therapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Sorrento Therapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Sorrento Therapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Sorrento Therapeutics, Inc. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Sorrento Therapeutics, Inc. :薬剤プロファイル

  • IG-002
  • paclitaxel-loaded polymeric micelle
  • resiniferatoxin
  • Antibody Drug Conjugate to Target CCR5 for Oncology
  • Biosimilar to Target CD20 for Oncology
  • Monoclonal Antibody for Oncology
  • Monoclonal Antibody to Inhibit Ghrelin for Obesity
  • Small Molecules to Inhibit c-Myc for Cancer
  • STI-001
  • STI-A020X
  • STIA-050X
  • STIA-100X
  • STIA-1010
  • STIA-1011
  • STIA-1012
  • STIA-1014
  • STIA-1110
  • STIA-120X
  • STIA-160X
  • STIA-220X
  • STIA-230X
  • STIB-010X
  • STIB-0201
  • STIB-030X
  • STIB-120X
  • STIB-150X
  • STIC-0205
  • STIC-020X
  • STID-0168
  • STID-0602
  • Clostridium difficile vaccine
  • Monoclonal Antibodies for Clostridium difficile
  • Monoclonal Antibodies for Hepatitis C

Sorrento Therapeutics, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Sorrento Therapeutics, Inc. :最新のパイプライン情報

Sorrento Therapeutics, Inc. :開発休止中の製品

Sorrento Therapeutics, Inc. :開発が中止されたパイプライン製品

Sorrento Therapeutics, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07398CDB

Summary

Global Markets Direct's, 'Sorrento Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Sorrento Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sorrento Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sorrento Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sorrento Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sorrento Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Sorrento Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sorrento Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sorrento Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sorrento Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sorrento Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sorrento Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sorrento Therapeutics, Inc. Snapshot
    • Sorrento Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Sorrento Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sorrento Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
  • Sorrento Therapeutics, Inc. - Pipeline Products Glance
  • Sorrento Therapeutics, Inc. - Late Stage Pipeline Products
  • Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products
  • Sorrento Therapeutics, Inc. - Early Stage Pipeline Products
  • Sorrento Therapeutics, Inc. - Drug Profiles
    • paclitaxel
    • resiniferatoxin
    • Cell Therapy to Target CD123 for Acute myeloid leukemia
    • Cell Therapy to Target PD-L1 for Oncology
    • Cell Therapy to Target PSMA for Prostate Cancer
    • Cell Therapy to Target ROR1 for Oncology
    • BA-0702
    • CBA-0710
    • Cell Therapy to Target c-KIT for Solid Tumors
    • Cell Therapy to Target CD33 for Acute Myeloid Leukemia
    • Cell Therapy to Target CS1 for Multiple Myeloma
    • Cell therapy to Target GD3 for Solid Tumors
    • Cell Therapy to Target HER2 for Oncology
    • Cell therapy to Target IL13R Alpha2 for Glioblastoma Multiforme
    • Cell Therapy to Target MUC-16 for Ovarian Cancer
    • Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer and Gastric Cancer
    • Monoclonal Antibody Conjugated to Target CXCR5 for Cancer
    • Monoclonal Antibody to Agonize OX40 for Oncology
    • Monoclonal Antibody to Inhibit CD47 for Cancer
    • Monoclonal Antibody to Inhibit Ghrelin for Obesity
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology
    • Monoclonal Antibody to Inhibit PD-L1 and CTLA-4 for Oncology
    • Monoclonal Antibody to Inhibit TIM-3 for Oncology
    • Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology
    • rituximab biosimilar
    • Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies
    • STIA-0168
    • STIA-020X
    • STIA-050X
    • STIA-100X
    • STIA-1010
    • STIA-1011
    • STIA-1012
    • STIA-1014
    • STIA-1110
    • STIA-120X
    • STIA-160X
    • STIA-220X
    • STIA-230X
    • STIB-010X
    • STIB-0201
    • STIB-030X
    • STIB-120X
    • STIB-150X
    • STIC-0205
    • STIC-020X
    • STID-0602
    • BC-001
    • Cell Therapy to Target BCMA for Myeloma
    • Cell Therapy to Target CD19 for CLL and ALL
    • Cell Therapy to Target CD22 for CLL and ALL
    • Cell Therapy to Target CSPG4 for Oncology
    • Cell Therapy to Target EGFR for Glioma
    • Cell Therapy to Target EPHA3 for Glioma
    • Cell Therapy to Target L1CAM for Oncology
    • Clostridium difficile vaccine
    • Monoclonal Antibodies for Clostridium difficile
    • Monoclonal Antibodies for Hepatitis C
    • STI-001
  • Sorrento Therapeutics, Inc. - Pipeline Analysis
    • Sorrento Therapeutics, Inc. - Pipeline Products by Target
    • Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Sorrento Therapeutics, Inc. - Recent Pipeline Updates
  • Sorrento Therapeutics, Inc. - Dormant Projects
  • Sorrento Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Sorrento Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sorrento Therapeutics, Inc., Key Information
  • Sorrento Therapeutics, Inc., Key Facts
  • Sorrento Therapeutics, Inc. - Pipeline by Indication, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Sorrento Therapeutics, Inc. - Phase III, 2015
  • Sorrento Therapeutics, Inc. - Phase II, 2015
  • Sorrento Therapeutics, Inc. - Phase I, 2015
  • Sorrento Therapeutics, Inc. - Preclinical, 2015
  • Sorrento Therapeutics, Inc. - Discovery, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Target, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Sorrento Therapeutics, Inc., Subsidiaries

List of Figures

  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Sorrento Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top